Basic Information
| LncRNA/CircRNA Name | LINC01551 |
| Synonyms | NA |
| Region | GRCh38_14:28772704-28813453 |
| Ensemble | ENSG00000186960 |
| Refseq | NR_026731 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot, Luciferase reporter assay, RIP |
| Sample | Normal human liver cell line L-02, and HCC cell lines MHCC97-H, HepG2, and SMCC7721, HCC, liver tissues, adjacent normal tissues |
| Expression Pattern | up-regulated |
| Function Description | High expression of LINC01551 and ADAM10 yet low-expression of miR-122-5p were revealed in HCC tissues and cells. Overexpression of miR-122-5p could downregulate ADAM10. Biological prediction websites and fluorescence in situ hybridization assay verified that LINC01551 was mainly expressed in the cytoplasm. Silencing LINC01551 reduced HCC cell viability, proliferation, migration, invasion, and cell cycle entry yet induce cell apoptosis. Upregulation of LINC01551 increased its ability of competitively binding to miR-122-5p, thus reducing miR-122-5p and upregulating ADAM10 expression, as well as promoting the proliferative, migrative, and invasive ability. |
| Pubmed ID | 31270840 |
| Year | 2019 |
| Title | Long noncoding LINC01551 promotes hepatocellular carcinoma cell proliferation, migration, and invasion by acting as a competing endogenous RNA ofmicroRNA-122-5p to regulate ADAM10 expression |
External Links
| Links for LINC01551 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |